NOREPINEPHRINE BITARTRATE Drug Patent Profile

When do Norepinephrine Bitartrate patents expire, and when can generic versions of Norepinephrine Bitartrate launch?

Norepinephrine Bitartrate is a drug marketed by Amneal, Anthea Pharma, Aspiro, Baxter Hlthcare Corp, Biocon Pharma, Breckenridge, Caplin, Fresenius Kabi Usa, Gland, Hikma, Meitheal, Metrics Pharm, MSN, Mylan Labs Ltd, Rising, Sandoz, Sun Pharm, Zydus Pharms, Inforlife, Long Grove Pharms, and Sagent. and is included in twenty-four NDAs. There are twelve patents protecting this drug.

The generic ingredient in NOREPINEPHRINE BITARTRATE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate

A generic version of NOREPINEPHRINE BITARTRATE was approved as norepinephrine bitartrate by MEITHEAL on March 3^rd, 2003.

Summary for NOREPINEPHRINE BITARTRATE

US Patents:	0
Applicants:	21
NDAs:	24
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NOREPINEPHRINE BITARTRATE

US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-002	Oct 6, 2022		RX	Yes	Yes	10,420,735		Y
Inforlife	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	215700-004	Oct 15, 2025		RX	Yes	Yes	RE49422		Y
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes	10,226,436		Y

Investment Scenario, Market Dynamics, and Financial Trajectory for Norepinephrine Bitartrate

Last updated: February 3, 2026

Summary

Norepinephrine bitartrate, a vasopressor used primarily for hypotension management, exhibits a stable yet niche market with potential growth driven by clinical demand, regulatory trends, and pipeline innovations. Its existing formulations face competition from alternatives like vasopressin. Over the next five years, the drug's financial trajectory will be shaped by factors including global healthcare policies, manufacturing capacity, patent status, and emerging biosimilar entries, with projected revenues stabilizing around $200 million annually in established markets. The market remains focused on hospital use, with untapped opportunities in emergent markets and novel delivery systems.

---

Market Overview & Industry Context

Market Size & Revenue Estimates

Parameter	2022 Data	2023 Trajectory Estimates	Comments
Global market value	~$250 million	+3-5% CAGR	Slight increase driven by clinical volume
Key regions	North America (50%), Europe (25%)	Steady growth expected	US dominates due to hospital use
Market penetration	70-80% in critical care settings	Stable with incremental growth	Use largely confined to hospitals

Key Industry Drivers

Driver	Impact	Notes
Clinical adoption	Maintains steady demand for vasopressors	Critical for shock management
Healthcare infrastructure	Expansion in emerging markets	Limited by infrastructure readiness
Regulatory policies	Approval pathways affect market access	Changes impact formulation approvals
Patent landscape & generics	Generic competition pressures	Patents expired in 201 Reactivating competition

Competitive Landscape & Product Portfolio

Competitor / Product	Formulation	Market share	Features and notes
Norepinephrine Bitartrate	Injectable (vial, prefilled)	~75%	Gold standard vasopressor
Vasopressin	Injectable	~10%	Alternative vasopressor, used in specific cases
Dopamine	Injectable	~10%	Replaced in many indications by norepinephrine
Emerging biosimilars	Varying formulations	0-5%	Potential future entrants

---

Financial Trajectory & Revenue Forecast

Revenue Drivers & Limiters

Driver	Effect	Assessment
Drug efficacy & safety profile	Ensures continued clinical necessity	Stable demand
Patent expiration & generics	Potential revenue erosion post patent expiry	Marginal impact in mature markets
Supply chain stability	Critical for consistent sales	Highly dependent on manufacturing
Regulatory approvals	Facilitates market expansion	Favorable in known markets, complex in new regions
Emerging market growth	Opens new revenue streams	Slower adoption, infrastructure dependency

Projected Revenue Range (2023–2028)

Year	Estimated Revenue (USD Millions)	Comments
2023	180 – 200	Baseline steady growth
2024	185 – 210	Slight increase due to market expansion
2025	190 – 220	Competition intensifies slightly
2026	195 – 225	Market saturation approaches in mature regions
2027	200 – 230	Potential entry of biosimilars
2028	205 – 235	Adjusted for competitive pressures

---

Market Dynamics Analysis

Supply & Manufacturing Trends

Aspect	Trends & Impacts	Outlook
Manufacturing capacity	Existing plants focused on U.S. and EU markets	Stable, with capacity expansions in process
Regulatory compliance	Emphasis on GMP standards	Ensures high production quality
Cost of goods sold (COGS)	Margins pressured by raw material costs	Expected to stabilize with process improvements

Regulatory & Policy Implications

• FDA & EMA approvals: Continued reliance on established approval pathways; expansions in indications or formulations require new filings.
• Pricing & reimbursement: Reimbursement rates remain stable in key markets; pressure from payers may influence pricing strategies.
• Patent landscape: Original patents expired or are nearing expiration; biosimilar entries anticipated, potentially reducing prices.

Emerging Opportunities & Risks

Opportunity	Risk	Strategy
Development of fixed-dose combinations	Regulatory hurdles, market acceptance	Invest in R&D and clinical trials
Expansion into biosimilars	Possible patent litigations, biosimilar acceptance	Engage proactively in patent landscapes
New delivery systems (e.g., infusion pumps)	Technological barriers, clinical validation needed	Collaborate with device innovators

---

Comparison with Alternatives & Biosimilar Threats

Aspect	Norepinephrine Bitartrate	Vasopressin / Alternatives	Biosimilars
Efficacy	High, primary vasopressor choice	Similar, used in specific cases	Expected to be equivalent
Market share	Dominant in hospitals	Niche, adjunct or alternative indications	Increasing, especially post-patent
Pricing	Premium due to stability & familiarity	Competitive, lower in some regions	Lower, pressure on prices
Regulatory hurdles	Minimal in mature markets	Similar, may vary regionally	Stringent in biosimilar approval

---

Deep Dive: Investment Summary

Category	Insights
Market attractiveness	Moderate; steady demand in critical care, limited in outpatient settings
Growth drivers	Hospital volume increases, pipeline innovation, emerging markets
Major risk factors	Patent expirations, generic competition, regulatory delays
Strategic recommendations	Focus on pipeline expansion, geographic diversification, and biosimilar readiness

---

Key Takeaways

• Market Stability: Norepinephrine bitartrate maintains a dominant position as first-line vasopressor in critical care with projected revenues approaching $200 million annually in mature markets.
• Competitive Landscape: Patent expirations and biosimilar entrants threaten pricing power but are countered by the drug’s clinical efficacy and hospital reliance.
• Growth Opportunities: Expansion into emerging markets, development of novel formulations, and pipeline innovation offer growth avenues.
• Risks & Challenges: Patent cliffs, regulatory complexities, and supply chain disruptions require proactive management.
• Investment Outlook: Moderate growth expected over the next five years with strategic positioning focusing on pipeline development and biosimilar preparedness.

---

FAQs

1. What is the current patent status of norepinephrine bitartrate?
   Most key patents have expired or are nearing expiration, opening the market to generic and biosimilar competitors (post-2023 in many regions).

2. How does biosimilar competition affect the market?
   Biosimilars are anticipated to exert downward pressure on prices, especially in regions with accelerated biosimilar approval pathways such as the EU and the U.S.

3. Are there emerging formulations of norepinephrine with potential market impact?
   Yes; fixed-dose combinations, sustained-release formulations, and delivery systems such as infusion pumps are under development, possibly affecting future demand.

4. What role do regulations play in the market's growth?
   Regulatory agencies like the FDA and EMA influence market entry and expansion; streamlined approval processes for established drugs facilitate growth but introduce competitive risks when biosimilars enter.

5. What are the primary factors influencing the revenue trajectory over the next five years?
   Key factors include patent expirations, market penetration in emerging economies, pipeline innovation, and competitive pricing from biosimilar entrants.

---

References

1. [1] IQVIA Institute. "Global Use of Medicines in 2022."
2. [2] FDA Drug Approvals & Biosimilar Guidelines, 2022–2023.
3. [3] MarketWatch. "Vasopressor Drugs Market Size and Trends," 2022.
4. [4] European Medicines Agency. "Biosimilars Approvals," 2023.
5. [5] S&P Capital IQ. "Pharmaceutical Market Analytics," 2023.

---

In conclusion, norepinephrine bitartrate remains a stable yet evolving segment within vasopressor therapies, with revenues expected to stay robust amid competition. Strategic investment should emphasize pipeline development and biosimilar integration to sustain growth.